Company intelligence / Profile preview

AGI Therapeutics plc

Ownership: Private
Development stage: Phase 3

Overview

The company's lead product Rezular (R-verapamil/arverapamil) completed Phase 3 clinical trials for IBS-D. AGI-010, a bimodal modified release once-daily formulation of omeprazole for GERD, demonstrated improved control of night-time acid compared to Prilosec.

Therapeutic areas: Gastroenterology
Modalities: Small moleculesdrug reprofiling/reformulation
Industry: Biotech

Drug pipeline

2 assets

omeprazole

Pre-clinical

Indications: Gastro-esophageal reflux disease

1 more asset in the full pipeline.

Request access →

Partnerships

Previously had partnership with Axcan Pharma Inc. (terminated in 2009)

Beyond the preview

Go deeper on AGI Therapeutics plc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGI Therapeutics plc.

Explore the full profile